The MetaVia Inc. (MTVA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer focused on cardiometabolic diseases. MetaVia files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-37809 as a Delaware corporation with principal offices in Cambridge, Massachusetts. These filings offer detailed information on clinical progress, financial results, capital market actions, and interactions with The Nasdaq Capital Market.
Among MetaVia’s recent filings are several Current Reports on Form 8-K that describe material events. One 8-K discusses a notice from Nasdaq regarding non-compliance with the minimum bid price requirement and a subsequent 180-day extension to May 26, 2026 to regain compliance, as well as the company’s intention to consider options such as a reverse stock split. Another 8-K references the company’s press release announcing a 1-for-11 reverse stock split of its common stock, which was implemented to help meet Nasdaq’s continued listing standards. A later press release, also furnished via 8-K, reports that MetaVia regained compliance with Nasdaq’s minimum bid price requirement and that the listing matter was closed.
Other 8-K filings furnish clinical and corporate updates, including positive Phase 2a data for vanoglipel (DA-1241) in presumed MASH patients and references to improvements in HbA1c, liver inflammation, fibrosis markers, and lipidomic profiles. MetaVia also uses Form 8-K to furnish its quarterly financial results and to provide access to updated corporate presentations, which summarize the status of its DA-1726 and vanoglipel programs and outline its cardiometabolic disease strategy.
Through Stock Titan, users can review these MetaVia SEC filings in one place and use AI-powered tools to summarize key points from complex disclosures. Filings such as 10-K annual reports, 10-Q quarterly reports, and additional 8-K current reports, when available, can help investors and analysts understand MetaVia’s R&D spending, clinical development milestones, capital structure changes, and Nasdaq listing compliance history. Insider transaction reports on Form 4, if filed, can also be accessed to see reported purchases or sales by MetaVia’s officers, directors, or significant shareholders.
MetaVia Inc. announced that an abstract featuring Phase 1 clinical-trial data for DA-1726 was accepted for an oral presentation at the Precision Liver Symposium 2026 on November 4, 2026, in Denver. DA-1726 is a dual GLP-1 and glucagon receptor agonist intended for once-weekly subcutaneous administration. MetaVia said the 32 mg dose in its Phase 1 multiple ascending dose trial in obesity demonstrated potential for weight loss, glucose control and waist-circumference reduction. The company also reported improvements in noninvasive measures of hepatic steatosis and liver stiffness in a Phase 1 trial. MetaVia described vanoglipel (DA-1241) as being developed for MASH and said it demonstrated direct hepatic action in a Phase 2a clinical study, alongside glucose-lowering effects.
MetaVia Inc. Chief Medical Officer Sarah Kaplan Browne received a grant of 53,000 restricted stock units on October 12, 2026. Her reported position following the transaction was 53,000 shares. The units vest 50% on each of the first and second anniversaries of the grant date, subject to her continuing service on each applicable vesting date.
MetaVia Inc.'s Form 3 identifies Sarah Kaplan Browne as its Chief Medical Officer.
MetaVia Inc. (MTVA) appointed Sarah Kaplan Browne, M.D., as Chief Medical Officer, effective October 12, 2026. She brings more than 20 years of experience in clinical development, regulatory science and clinical medicine, including expertise in liver and metabolic diseases such as MASH. Her background includes leading pemvidutide’s clinical development through Phase 2 and establishing Phase 3 development strategies.
MetaVia anticipates a fourth-quarter 2026 topline data readout from Part 3 of the Phase 1 trial of DA-1726, which evaluates higher target doses of 48 mg and 64 mg. The company is also developing DA-1726 for cardiometabolic indications and vanoglipel (DA-1241) for MASH.
MetaVia Inc. (MTVA) reported new preclinical data from its DA-1726 tissue distribution study, showing that DA-1726-derived radioactivity is slowly absorbed and extensively distributed after subcutaneous dosing, with the highest exposure in adipose (fat) tissue and prolonged retention in tissues relative to plasma through the 144-hour assessment.
The company links these findings to previously reported Phase 1 results in obesity, where the 48 mg dose of DA-1726 produced a 9.8 cm mean reduction in waist circumference after eight weeks of treatment. The preclinical profile supports once-weekly dosing and suggests limited brain penetration, with only minimal radioactivity detected in the central nervous system, consistent with peptide-based therapies.
MetaVia states that these data provide mechanistic support for DA-1726’s differentiated profile as a GLP1R/GCGR dual agonist obesity candidate and notes that an ongoing 24-week dose-titration study is underway, with 16-week topline data expected in the fourth quarter of 2026 and 24-week topline results in the first quarter of 2027.
MetaVia Inc., a clinical-stage biotech focused on cardiometabolic diseases, reported a net loss of $5.3 million for the quarter and $9.1 million for the six months ended June 30, 2026, driven by $9.4 million in combined research and development and general and administrative expenses.
Cash and cash equivalents were $12.6 million at June 30, 2026, up from $10.3 million at year-end, helped by a January 2026 underwritten equity offering, at-the-market sales, and warrant exercises that together provided $10.4 million of financing in the first half.
MetaVia highlights that its recurring losses, negative operating cash flows and limited cash raise substantial doubt about its ability to continue as a going concern within one year without additional capital. The company continues Phase 2a development of vanoglipel for MASH and Phase 1 trials of DA-1726 for obesity, with key data readouts planned in the fourth quarter of 2026.
MetaVia Inc. reported second-quarter 2026 results and progress in its cardiometabolic pipeline, including obesity candidate DA-1726 and liver/metabolic candidate vanoglipel (DA-1241).
For the six months ended June 30, 2026, R&D expenses were approximately $5.6 million and G&A expenses were approximately $3.8 million, resulting in a net loss of approximately $9.1 million, or $1.69 per share, compared with a net loss of approximately $7.7 million a year earlier. Cash and cash equivalents were $12,634 thousand and total stockholders’ equity was $6,822 thousand as of June 30, 2026.
All active patients in both cohorts of the Phase 1 Part 3 study of DA-1726 reached the highest planned 48 mg and 64 mg dose levels, with 16-week topline data expected in the fourth quarter of 2026. Earlier Phase 1 data at 48 mg showed up to 9.1% mean weight loss after eight weeks, with reductions in waist circumference and encouraging liver-related findings. MetaVia also highlighted preclinical and clinical findings supporting vanoglipel as a potential combination backbone for metabolic and liver diseases.
MetaVia Inc. reported a key operational milestone in its obesity program. All enrolled active patients in Part 3 of its Phase 1 trial of DA-1726 have completed dose titration and are now receiving their highest target doses of 48 mg and 64 mg in the two cohorts.
Part 3 includes two 16-week titration regimens designed to test one-step and two-step dose escalation, with about 40 obese but otherwise healthy adults randomized 4:1 to active drug versus placebo. The company reiterated that topline data from this Phase 1 Part 3 study remain on track for release in the fourth quarter of 2026.
MetaVia highlighted earlier Phase 1 multiple ascending dose results where DA-1726 produced 9.1% mean weight loss at the 48 mg dose over 8 weeks, along with improvements in waist circumference, glycemic control, and early liver signals, supporting the potential of its dual GLP-1/glucagon mechanism in obesity and related metabolic disease.
MetaVia Inc. filed a Form 8-K to report a prospectus supplement tied to its existing at-the-market equity program. The company may sell up to $4,000,000 of common stock through or to Ladenburg Thalmann & Co. Inc. under a previously signed At The Market Offering Agreement.
Honigman LLP issued a legal opinion on the validity of the shares that may be issued under this arrangement, which is included as Exhibit 5.1. The filing clarifies that it is not itself an offer to sell securities and that any sales must comply with applicable state and federal securities laws.
Metavia Inc. registers the offer and sale of up to an aggregate offering price of $4,000,000 of its common stock under an At-The-Market sales agreement with Ladenburg Thalmann & Co. Inc.
The supplement increases the prior ATM capacity from $2,300,000. Through the date of the supplement the company sold $2,126,303 of common stock under the Sales Agreement. The filing cites a last reported sales price of $1.45 per share on July 1, 2026 and an aggregate market value of shares held by non-affiliates of $18,438,694 based on 4,789,271 shares at $3.85 per share on May 22, 2026.